Monitoring receptor heterodimerization along intracellular trafficking pathways using anti-HER2 therapeutic antibodies

Alena Rudkouskaya; Jason Smith; Xavier Intes; Margarida Barroso

doi:10.1117/12.2578402

12 March 2021 Monitoring receptor heterodimerization along intracellular trafficking pathways using anti-HER2 therapeutic antibodies

Alena Rudkouskaya, Jason Smith, Xavier Intes, Margarida Barroso

Author Affiliations +

Proceedings Volume 11624, Visualizing and Quantifying Drug Distribution in Tissue V; 116240F (2021) https://doi.org/10.1117/12.2578402
Event: SPIE BiOS, 2021, Online Only

Abstract

Overexpression of Human EGF Receptor 2 (HER2) in cancer is a marker of aggressive metastatic disease and poor prognosis. Anti-HER2 humanized monoclonal antibody trastuzumab (TZM) has been successfully used in the clinic over the last decades. However, a large fraction of eligible patients display resistance to this therapy. This calls for a deeper investigation of HER2 interaction with other members of HER tyrosine kinase receptors and modulation of their endocytic trafficking upon TZM treatment. Forster resonance energy transfer Fluorescence lifetime microscopy (FLIM- FRET) offers a robust approach to monitor HER2 homo and heterodimerization via the reduction of donor fluorophore lifetime. The objective of this study was to assess the dynamics of HER receptor homo and heterodimerization behavior via FLIMFRET by using near-infrared (NIR) FRET pair labeled anti-HER2 and anti-EGFR therapeutic antibodies in HER2- overexpressing breast cancer cells. In addition, we tested our new deep learning platform DL4FLIM adapted for automated analysis of all datasets. Herein, we report a first attempt to quantify NIR FRET pair labeled cetuximab (CTM, as a donor) and TZM (as an acceptor) binding to their receptors EGFR and HER2 respectively in AU565 cells. As a control, we also performed and human isotype IgG FLIM -FRET and found it completely non-specific. Our data demonstrate both the occurrence of FRET between NIR-labeled probes CTM and TZM as well as between CTM-CTM bound to their respective receptors. This proof-of -principal study demonstrated feasibility of monitoring HER2 hetero receptor FRET FLIM to better understand mechanism of TZM resistance.

Conference Presentation

Citation Download Citation

Alena Rudkouskaya, Jason Smith, Xavier Intes, and Margarida Barroso "Monitoring receptor heterodimerization along intracellular trafficking pathways using anti-HER2 therapeutic antibodies", Proc. SPIE 11624, Visualizing and Quantifying Drug Distribution in Tissue V, 116240F (12 March 2021); https://doi.org/10.1117/12.2578402

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available